Review Explores Safety and Efficacy of Growth Hormone Secretagogues
Background
Growth Hormone Secretagogues (GHS) are compounds designed to stimulate the body's natural production and release of Growth Hormone (GH) from the pituitary gland. These peptides and small molecules are often explored for their potential benefits in areas like muscle growth, fat loss, and anti-aging, particularly in conditions like GH deficiency or sarcopenia (age-related muscle loss). Despite their increasing popularity, a comprehensive understanding of their overall safety profile and clinical efficacy across various populations has been fragmented, making a consolidated review of the existing literature crucial to address the knowledge gap regarding their therapeutic potential and associated risks.
Results
The review found that GHS consistently and significantly increased GH pulsatility by an average of 2 to 3.5-fold and elevated Insulin-like Growth Factor 1 (IGF-1) levels by 30-60% across most studies. In older adults, GHS treatment for 3-6 months typically resulted in a 2-5% increase in lean body mass and a 1-3% reduction in fat mass, though these changes were often modest. Common side effects reported included mild edema (15-25% of users), increased appetite (20-35%), and transient glucose intolerance (5-10%), particularly with higher doses or specific compounds like MK-677. The most critical finding was that while GHS effectively elevate GH and IGF-1, their long-term safety profile, especially concerning potential risks like cardiovascular events, cancer progression, or glucose dysregulation, remains inconclusive due to a lack of sufficiently powered, long-duration human trials.
Why It Matters
This comprehensive review underscores the therapeutic promise of GHS for conditions characterized by GH deficiency or age-related decline, such as sarcopenia and frailty, by effectively stimulating endogenous GH release. The findings suggest that GHS could offer a safer alternative to exogenous GH administration in certain contexts, potentially leading to new clinical applications for improving body composition and metabolic health. However, the identified gaps in long-term safety data highlight the urgent need for larger, placebo-controlled Phase II and Phase III human trials to fully elucidate the risk-benefit profile of these compounds before widespread clinical adoption.